Press release
Gene and Cell Therapies Targeting CNS Disorders Market Growth, Applications, Innovations and Business Outlook by 2034
Gene and Cell Therapies Targeting CNS Disorders Market
Introduction
Central Nervous System (CNS) disorders-ranging from Parkinson's disease and Alzheimer's to multiple sclerosis and rare neurogenetic conditions-represent one of the most challenging areas of modern medicine. Traditional therapies often manage symptoms but rarely alter the course of disease progression. This unmet need has fueled an explosion of interest in gene and cell therapies that target the root causes of neurological dysfunction.
By leveraging cutting-edge platforms like adeno-associated virus (AAV)-based gene delivery, CRISPR editing, and stem cell transplantation, biotech companies are pushing the boundaries of neurotherapeutics. The gene and cell therapies targeting CNS disorders market, valued at USD $12 billion in 2024, is expected to grow to USD $28 billion by 2034, expanding at a remarkable CAGR of 8.5%.
This growth is supported by expanding clinical pipelines, rising prevalence of neurological disorders, and significant investments from both pharma and venture capital.
Download Full PDF Sample Copy of Market Report @
https://exactitudeconsultancy.com/request-sample/70785
Market Overview
• Market Size (2024): USD $12 billion
• Forecasted Market Size (2034): USD $28 billion
• CAGR (2024-2034): 8.5%
• Key Drivers: Rising incidence of neurodegenerative and genetic CNS disorders, rapid clinical trial advancements, and increasing R&D investments.
• Key Challenges: High development costs, complex regulatory pathways, and safety concerns with long-term gene editing.
• Leading Players: Novartis, Biogen, Bluebird Bio, Roche, Spark Therapeutics, and others.
The market is still emerging but represents one of the most promising segments of the global biotechnology industry, with strong potential for breakthrough treatments.
Segmentation Analysis
By Therapy Type
• Gene Therapy (in vivo & ex vivo approaches)
• Stem Cell Therapy
• CAR-T & Immunotherapies for CNS
• Combination Therapies
By Vector/Delivery Method
• Adeno-Associated Virus (AAV)
• Lentiviral Vectors
• Retroviral Vectors
• Non-viral Platforms (nanoparticles, liposomes)
By Application
• Parkinson's Disease
• Alzheimer's Disease
• Amyotrophic Lateral Sclerosis (ALS)
• Multiple Sclerosis
• Huntington's Disease
• Rare Genetic CNS Disorders (e.g., spinal muscular atrophy, Batten disease)
By End Use
• Hospitals & Specialty Clinics
• Research & Academic Institutes
• Biopharma R&D Centers
By Region of Use
• Developed Economies (North America, Europe)
• Emerging Economies (APAC, Latin America, MEA)
Segmentation Summary:
Gene therapy dominates in the rare disease segment (notably spinal muscular atrophy treatments), while stem cell-based approaches are gaining traction for regenerative applications in Parkinson's and multiple sclerosis. AAV remains the leading vector due to its strong safety profile and effectiveness in crossing the blood-brain barrier.
Explore Full Report here:
https://exactitudeconsultancy.com/reports/70785/gene-and-cell-therapies-targeting-cns-disorders-market
Regional Analysis
North America
• Largest market due to advanced biotech ecosystems, strong funding networks, and rapid FDA approvals for orphan drugs.
• U.S. dominates global clinical trials for CNS-targeted gene therapies.
Europe
• Strong R&D landscape with Germany, France, and the UK leading in rare disease and CNS-focused research.
• EMA's supportive orphan drug framework is accelerating approvals.
Asia-Pacific (APAC)
• Fastest-growing region, with China and Japan investing heavily in regenerative medicine and gene editing.
• Rising incidence of neurodegenerative conditions and large patient base drive demand.
Middle East & Africa (MEA)
• Emerging opportunities with governments expanding access to advanced therapies.
• Still faces cost and infrastructure challenges.
Latin America
• Brazil and Mexico are growing contributors with expanding clinical trial participation and investments in advanced healthcare infrastructure.
Regional Summary:
While North America and Europe dominate revenue, Asia-Pacific is set to become the growth engine for the next decade, driven by demographic trends, regulatory support, and expanded biotech manufacturing capabilities.
Market Dynamics
Key Growth Drivers
• Rising burden of CNS disorders worldwide.
• Breakthroughs in gene-editing tools like CRISPR and advanced viral vectors.
• Strong funding landscape with venture capital and government grants.
• Orphan drug incentives accelerating development for rare neurogenetic diseases.
Key Challenges
• High costs of therapy development and treatment (often exceeding USD 1-2 million per patient).
• Long-term safety and efficacy concerns.
• Stringent and lengthy regulatory approval processes.
• Limited healthcare infrastructure for advanced biologics in low-income regions.
Latest Trends
• Increasing approvals of one-time curative gene therapies (e.g., Zolgensma for SMA as precedent).
• Rising interest in allogeneic stem cell approaches for scalable treatments.
• Growth of non-viral delivery platforms to address safety and scalability issues.
• Expansion of real-world evidence studies to track long-term outcomes.
Get Your Exclusive Offer with up to 10% Discount :
https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=70785
Competitor Analysis
Major Players in the Gene and Cell Therapies Targeting CNS Disorders Market:
1. Novartis AG (Zolgensma)
2. Biogen Inc.
3. Bluebird Bio, Inc.
4. Spark Therapeutics (Roche subsidiary)
5. Roche Holding AG
6. Voyager Therapeutics
7. Sangamo Therapeutics, Inc.
8. REGENXBIO Inc.
9. uniQure N.V.
10. Neurogene Inc.
11. Editas Medicine, Inc.
12. CRISPR Therapeutics AG
13. Intellia Therapeutics
14. Passage Bio, Inc.
15. Astellas Pharma Inc.
Competitive Summary:
The market is dominated by biotech innovators, with Novartis, Biogen, and Roche leading in approvals and clinical-stage assets. Emerging biotechs like Voyager and REGENXBIO are advancing novel AAV vectors. Partnerships between pharma giants and academic research institutions remain critical for accelerating discovery and commercialization.
Conclusion
The gene and cell therapies targeting CNS disorders market represents a paradigm shift in neurology, moving from symptom management to disease-modifying or curative treatments. While challenges remain around affordability and regulatory complexity, the sector is set for extraordinary growth over the next decade.
• North America and Europe remain dominant hubs for innovation.
• Asia-Pacific is emerging as the fastest-growing market.
• Gene therapies and AAV vectors will dominate near-term adoption, with stem cell and non-viral platforms growing rapidly.
This report is also available in the following languages : Japanese (中枢神経系疾患市場をターゲットとした遺伝子・細胞治療), Korean (중추신경계 질환을 타깃으로 하는 유전자 및 세포 치료제 시장), Chinese (针对中枢神经系统疾病的基因和细胞疗法市场), French (Marché des thérapies géniques et cellulaires ciblant les troubles du système nerveux central), German (Markt für Gen- und Zelltherapien zur Behandlung von ZNS-Erkrankungen), and Italian (Mercato delle terapie geniche e cellulari mirate ai disturbi del sistema nervoso centrale), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @
https://exactitudeconsultancy.com/request-sample/70785
Our More Reports:
Muscle Invasive Bladder cancer Market
https://exactitudeconsultancy.com/reports/71249/muscle-invasive-bladder-cancer-market
Mycosis Fungoides Market
https://exactitudeconsultancy.com/reports/71250/mycosis-fungoides-market
Pancreatic Adenocarcinoma Market
https://exactitudeconsultancy.com/reports/71251/pancreatic-adenocarcinoma-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
IRFAN TAMBOLI
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Gene and Cell Therapies Targeting CNS Disorders Market Growth, Applications, Innovations and Business Outlook by 2034 here
News-ID: 4147998 • Views: …
More Releases from Exactitude Consultancy
Hypertrophic Cardiomyopathy Market to Reach USD 3.21 Billion by 2034, Growing at …
Introduction
Hypertrophic cardiomyopathy (HCM) is a genetic heart disorder characterized by abnormal thickening of the heart muscle, which can impair blood flow and increase the risk of arrhythmias, heart failure, and sudden cardiac death. Once managed primarily through beta-blockers, calcium channel blockers, and invasive procedures, the HCM treatment landscape has expanded with the approval of targeted therapies such as cardiac myosin inhibitors.
Growing awareness of genetic cardiovascular diseases, advances in molecular diagnostics,…
Biologics Contract Research Organization (CRO) Market to Reach USD 37.9 Billion …
Introduction
Biologics-including monoclonal antibodies, vaccines, recombinant proteins, and advanced therapies-are at the forefront of modern medicine. Their development, however, requires significant expertise, advanced infrastructure, and compliance with stringent regulatory standards. To meet these demands, pharmaceutical and biotechnology companies are increasingly outsourcing to Contract Research Organizations (CROs) specializing in biologics.
Biologics CROs provide services spanning discovery, preclinical research, clinical trials, bioanalytical testing, and regulatory consulting. With the rise of biologics, biosimilars, and advanced…
Niemann-Pick Disease Market to Reach USD 1.02 Billion by 2034, Growing at 10.6% …
Introduction
Niemann-Pick disease (NPD) is a group of rare, inherited lysosomal storage disorders caused by mutations that disrupt lipid metabolism, leading to progressive neurological decline, organ dysfunction, and premature death. The condition is categorized into several subtypes (A, B, and C), each varying in severity and progression.
Historically, treatment has been limited to palliative and supportive care. However, the landscape is changing rapidly with the development of enzyme replacement therapies (ERT), substrate…
PERK Inhibitors Market Forecast: USD 3.2 Billion by 2034 | Major Participants: N …
The fight against cancer and neurodegenerative diseases has brought the spotlight on the PERK (Protein kinase RNA-like endoplasmic reticulum kinase) pathway, a critical regulator of the unfolded protein response. PERK inhibitors are designed to modulate this pathway, reducing stress-induced cell death and playing a pivotal role in oncology, neurodegenerative research, and metabolic disorders. As precision medicine continues to gain traction, PERK inhibitors are attracting significant attention from both biotech firms…
More Releases for CNS
CNS promotes craftsmanship of towel production in China
[https://youtu.be/oP-N73N0ey0]
China News Service (CNS) issued a press release and a promo video here on Wednesday to promote the unique craftsmanship of towel production in Gaoyang [https://youtu.be/oP-N73N0ey0] County of Chinese northern Hebei Province.
According to the CNS press release, Gaoyang is the largest hub of towel production in China, where one out of every three towels in the nation originates. More than 4200 textile enterprises are competing to flourish in this region,…
Gene Therapy in CNS Disorder Market - Unlocking the Potential of Gene Therapy: T …
Newark, New Castle, USA: The "Gene Therapy in CNS Disorder Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
Gene Therapy in CNS Disorder Market: https://www.growthplusreports.com/report/gene-therapy-in-cns-disorder-market/8886
This latest report…
Central Nervous System (CNS) Therapeutic Market Central Nervous System (CNS) The …
MARKET INTRODUCTION
The central nervous system (CNS) is the control panel of the body, which is responsible for cognition, movement, senses and emotions. Central nervous system diseases, is a group of neurological disorders that affect the structure or function of the brain or spinal cord, which collectively form the central nervous system (CNS). The CNS diseases include neurodegenerative diseases, neurodevelopmental diseases and traumatic injuries. Drugs such as analgesics, anesthetics, nervous system…
Neuro Critical Care Market Insights in terms of volume and value 2018 to 2028(Mo …
Neuro critical care is an emerging field that combines the specialties that link neurology, neurosurgery, and critical care. Just as the field has evolved from primary focus on post-operative care to elective neurosurgical patients, the focus towards the resuscitation of neurological emergency cases such as traumatic brain injury or subarachnoid hemorrhage, which remain a clinical challenge. The neuro critical care market is strongly driven by the increasing focus, awareness, and…
US CNS Disorders Drug Pipeline Insight 2014
The Central Nervous System (CNS) disorders market in US is one of the largest segments of pharmaceuticals industry. In US, the numbers of CNS disorders have increased at an alarming rate, while the available therapies were unable to meet the market requirements. There has been steady to rapid growth in the market for CNS disorder, especially over the past two decades. The market for CNS therapies is one of the…
CNS Therapeutics Market Research Report 2016
“Global CNS Therapeutics Market Research Report 2016” Order This Report by calling BigMarketResearch.com at +1-971-202-1575
Notes:
Production, means the output of CNS Therapeutics
Revenue, means the sales value of CNS Therapeutics
This report studies CNS Therapeutics in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with Production, price, revenue and market share for each manufacturer, covering
Pfizer, Inc. (USA)
Johnson & Johnson (USA)
Bristol-Myers Squibb…
